AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal violence (including child sexual abuse, physical violence, domestic violence, sexual assault)
Number of subjects: 733
Study 39246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic violence
Number of subjects: 733
Study 39246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder
Number of subjects: 733
Study 39246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health counseling
Number of subjects: 733
Study 39246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health medication
Number of subjects: 733
Study 39246931 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lifitegrast ophthalmic solution
Number of subjects: 32
Study 39246931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle solution)
Number of subjects: 32
Study 39247158 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue protocol
Number of subjects: 0
Study 39247158 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39247614 — intervention group
Group type: EXPERIMENTAL
Intervention: Box breathing
Number of subjects: 0
Study 39247614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing exercise
Number of subjects: 0
Study 39247614 — intervention group
Group type: COMPARATOR
Intervention: Everyday life (control)
Number of subjects: 0
Study 39247678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 199
Study 39247678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 39247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg mAb therapy
Number of subjects: 0
Study 39247686 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 39247962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 90
Study 39247962 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90
Study 39247971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 30
Study 39247971 — intervention group
Group type: COMPARATOR
Intervention: Control (angiography)
Number of subjects: 30
Study 39248107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg) and Minocycline (100 mg) - dual therapy for 12 weeks
Number of subjects: 19
Study 39248107 — intervention group
Group type: COMPARATOR
Intervention: Minocycline (100 mg) or Lovastatin (40 mg) - monotherapy for 8 weeks
Number of subjects: 19
Study 39248112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-obesity group 1 (defined by waist circumference > 96 cm)
Number of subjects: 36
Study 39248112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-obesity group 2 (defined by BMI > 26.5 kg/m2)
Number of subjects: 36
Study 39248112 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group 1
Number of subjects: 36
Study 39248112 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group 2
Number of subjects: 36
Study 39248170 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening for AF with continuous ECG for 3-7 days using ECG247 device.
Number of subjects: 35000
Study 39248170 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapy initiated if AF is detected.
Number of subjects: 35000
Study 39248170 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 5 years through national health registries.
Number of subjects: 35000
Study 39248249 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2910
Study 39248249 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2910
Study 39248270 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 150
Study 39248270 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 150
Study 39248270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronic acid
Number of subjects: 150
Study 39248270 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 150
Study 39248314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazzaferro's Metroticket 2.0 model for survival prediction
Number of subjects: 428
Study 39248314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazzaferro's Metroticket 2.0 model
Number of subjects: 428
Study 39248309 — intervention group
Group type: EXPERIMENTAL
Intervention: Depemokimab (100 mg subcutaneously at weeks 0 and 26)
Number of subjects: 762
Study 39248309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 762
Study 39248309 — intervention group
Group type: EXPERIMENTAL
Intervention: Depemokimab
Number of subjects: 762
Study 39248309 — intervention group
Group type: COMPARATOR
Intervention: Depemokimab and Placebo
Number of subjects: 762
Study 39248631 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39248780 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan
Number of subjects: 746
Study 39248780 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 746
Study 39249590 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate (800 mg) with sodium alginate (500 mg), sodium bicarbonate (267 mg), and simethicone (120 mg)
Number of subjects: 10
Study 39249590 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 10
Study 39249590 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate (800 mg)
Number of subjects: 10
Study 39249591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg subcutaneously every two weeks
Number of subjects: 0
Study 39249605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab (200 mg, IV every 3 weeks for 18 cycles)
Number of subjects: 25
Study 39249605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab
Number of subjects: 25
Study 39250131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi) with six weekly phone calls and assigned treatment manual readings.
Number of subjects: 178
Study 39250131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi)
Number of subjects: 178
Study 39250131 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 178
Study 39250138 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Number of subjects: 60
Study 39250138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39250153 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention group (pretest genetics education chat)
Number of subjects: 3073
Study 39250153 — intervention group
Group type: COMPARATOR
Intervention: Enhanced SOC control group (pretest genetic counseling appointment)
Number of subjects: 3073
Study 39250155 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult Error Management Training (EMT)
Number of subjects: 212
Study 39250155 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Error Management Training (EMT)
Number of subjects: 212
Study 39250155 — intervention group
Group type: COMPARATOR
Intervention: Error Avoidance Training (EAT) control
Number of subjects: 212
Study 39250182 — intervention group
Group type: EXPERIMENTAL
Intervention: Email delivery of supportive messages for 6 weeks
Number of subjects: 66
Study 39250182 — intervention group
Group type: COMPARATOR
Intervention: SMS text messaging delivery of supportive messages for 6 weeks
Number of subjects: 66
Study 39250213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced WeChat mini program
Number of subjects: 247
Study 39250213 — intervention group
Group type: COMPARATOR
Intervention: Standard WeChat mini program
Number of subjects: 247
Study 39250216 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH dashboards
Number of subjects: 62
Study 39250216 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 62
Study 39250243 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive preventive interventions
Number of subjects: 30
Study 39250283 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback training (8 sessions with physiological monitoring)
Number of subjects: 30
Study 39250283 — intervention group
Group type: COMPARATOR
Intervention: Control (physiological monitoring only)
Number of subjects: 30
Study 39250326 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3858279 (monoclonal antibody against CCL17)
Number of subjects: 21
Study 39250326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% w/v NaCl)
Number of subjects: 21
Study 39250326 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3858279
Number of subjects: 21
Study 39250326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 39250328 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom Motor Execution (PME)
Number of subjects: 81
Study 39250328 — intervention group
Group type: COMPARATOR
Intervention: Phantom Motor Imagery (PMI)
Number of subjects: 81
Study 39250514 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure system (BP monitor and mobile phone program)
Number of subjects: 949
Study 39250514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-monitoring BP system)
Number of subjects: 949
Study 39250515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg
Number of subjects: 966
Study 39250515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom 100 mg
Number of subjects: 966
Study 39250515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom (80 mg and 100 mg pooled)
Number of subjects: 966
Study 39250515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study 39250617 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic immunosuppression
Number of subjects: 35
Study 39250617 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 35
Study 39250646 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer delivery of oral-fluid HIVST, STISS, and PrEP refills
Number of subjects: 82
Study 39250646 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with quarterly in-clinic HIV testing and PrEP refills
Number of subjects: 82
Study 39250643 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP stigma
Number of subjects: 235
Study 39250643 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated HIV stigma
Number of subjects: 235
Study 39250647 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) via internet platforms, mailed to participants, with follow-up after 4 months.
Number of subjects: 2195
Study 39250647 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) via dating platforms.
Number of subjects: 2195
Study 39250651 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + FTC/TAF
Number of subjects: 643
Study 39250651 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + FTC/TDF
Number of subjects: 643
Study 39250651 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 643
Study 39250651 — intervention group
Group type: COMPARATOR
Intervention: DTG + FTC/TAF, DTG + FTC/TDF, EFV/FTC/TDF
Number of subjects: 643
Study 39250708 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous decitabine at 0.3 mg/kg per day for 10 days
Number of subjects: 21
Study 39250723 — intervention group
Group type: EXPERIMENTAL
Intervention: MOG-AR score developed from the cohort
Number of subjects: 188
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS) at diagnosis
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS) at four years post-diagnosis
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous psychiatric disorders
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS)
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 3555
Study 39250750 — intervention group
Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 3555
Study 39250787 — intervention group
Group type: EXPERIMENTAL
Intervention: Meds@HOME intervention
Number of subjects: 456
Study 39250787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not trialing Meds@HOME)
Number of subjects: 456
Study 39250792 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port robotic right colectomy
Number of subjects: 30
Study 39250792 — intervention group
Group type: COMPARATOR
Intervention: Multiport right colectomy
Number of subjects: 30
Study 39250887 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), administered with mask oxygen therapy of 10 L/min.
Number of subjects: 284
Study 39250887 — intervention group
Group type: COMPARATOR
Intervention: Sham NBO (1 L/min) combined with endovascular treatment (EVT).
Number of subjects: 284
Study 39250887 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO combined with EVT
Number of subjects: 284
Study 39250922 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor plus standard-of-care
Number of subjects: 575
Study 39250922 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 575
Study 39251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive ablation (PVI-plus group)
Number of subjects: 497
Study 39251131 — intervention group
Group type: COMPARATOR
Intervention: PVI-alone (PVI-alone group)
Number of subjects: 497
Study 39251349 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily in continuous 28-day cycles)
Number of subjects: 20
Study 39251366 — intervention group
Group type: EXPERIMENTAL
Intervention: TICK-B (colouring book) and TKTX cream (topical anaesthetic)
Number of subjects: 176
Study 39251366 — intervention group
Group type: COMPARATOR
Intervention: TKTX cream (topical anaesthetic)
Number of subjects: 176
Study 39251366 — intervention group
Group type: COMPARATOR
Intervention: TICK-B (colouring book)
Number of subjects: 176
Study 39251447 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Meals on Prescription (FMP) combined with lifestyle treatment
Number of subjects: 89
Study 39251447 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle treatment alone (Control)
Number of subjects: 89
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintensive care syndrome (PICS) follow-up
Number of subjects: 142
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up over 12 months
Number of subjects: 142
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical HRQoL scores
Number of subjects: 142
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental HRQoL scores
Number of subjects: 142
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter ICU stay, better functionality, lower scores for fatigue/dyspnea and pain
Number of subjects: 142
Study 39251486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower scores for anxiety, depression, and PTSD
Number of subjects: 142
Study 39251561 — intervention group
Group type: COMPARATOR
Intervention: Gatralimab administered via subcutaneous (SC) and intravenous (IV) routes, with doses of 1, 3.5, and 12 mg IV and 12, 36, and 60 mg SC.
Number of subjects: 0
Study 39251561 — intervention group
Group type: COMPARATOR
Intervention: Gatralimab SC (36, 48, or 60 mg) with different comedications.
Number of subjects: 0
Study 39251561 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone and antihistamine comedications.
Number of subjects: 0
Study 39251561 — intervention group
Group type: COMPARATOR
Intervention: Long-term safety study (NCT02313285).
Number of subjects: 0
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower volume administration and higher vasoactive support (postoperative hemodynamic management)
Number of subjects: 265
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 265
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance
Number of subjects: 265
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine administration
Number of subjects: 265
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid output
Number of subjects: 265
Study 39251616 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss
Number of subjects: 265
Study 39251643 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxing group (BG)
Number of subjects: 60
Study 39251643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular stabilization group (SSG)
Number of subjects: 60
Study 39251643 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 39251831 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS (n=63)
Number of subjects: 131
Study 39251831 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS (n=68)
Number of subjects: 131
Study 39251903 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC ≥ 102 cm for men and ≥ 88 cm for women)
Number of subjects: 2806
Study 39251903 — intervention group
Group type: COMPARATOR
Intervention: Normal waist circumference (not specified)
Number of subjects: 2806
Study 39251972 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online training modules
Number of subjects: 82
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term indoor PM exposure
Number of subjects: 95
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-term indoor PM exposure
Number of subjects: 95
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term indoor PM exposure
Number of subjects: 95
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term estimated PM exposure
Number of subjects: 95
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-term estimated PM exposure
Number of subjects: 95
Study 39251997 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term estimated PM exposure
Number of subjects: 95
Study 39252005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based contact management intervention
Number of subjects: 60
Study 39252005 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-shared intervention between health extension workers and facility-based TB focal persons
Number of subjects: 60
Study 39252005 — intervention group
Group type: EXPERIMENTAL
Intervention: Community awareness initiatives
Number of subjects: 60
Study 39252005 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralization of TPT
Number of subjects: 60
Study 39252007 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus isolates from clinical infection among neonates
Number of subjects: 132
Study 39252007 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus associated with clinical infection
Number of subjects: 132
Study 39252007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal S. aureus colonization
Number of subjects: 132
Study 39252018 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 229
Study 39252084 — intervention group
Group type: EXPERIMENTAL
Intervention: PLACES intervention (n=82)
Number of subjects: 164
Study 39252084 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group, n=82)
Number of subjects: 164
Study 39252106 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care (day-surgery)
Number of subjects: 1400
Study 39252106 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient care (overnight hospitalization)
Number of subjects: 1400
Study 39252179 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium binders (sodium polystyrene sulfonate, calcium polystyrene sulfonate, sodium zirconium cyclosilicate)
Number of subjects: 600
Study 39252484 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent music reward therapy (GC-MRT)
Number of subjects: 81
Study 39252484 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 81
Study 39252484 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 81
Study 39252529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase and intrathecal idursulfase-IT
Number of subjects: 7
Study 39252529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT
Number of subjects: 7
Study 39252529 — intervention group
Group type: COMPARATOR
Intervention: No idursulfase-IT
Number of subjects: 7
Study 39252547 — intervention group
Group type: EXPERIMENTAL
Intervention: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Number of subjects: 216
Study 39252547 — intervention group
Group type: COMPARATOR
Intervention: usual primary care
Number of subjects: 216
Study 39252591 — intervention group
Group type: EXPERIMENTAL
Intervention: Commissural alignment (CA) strategy attempted in 215 patients (38.6%) with self-expandable TAVR devices (Evolut Pro/Pro+ and Acurate neo2).
Number of subjects: 557
Study 39252591 — intervention group
Group type: COMPARATOR
Intervention: Moderate/severe CMA in patients without CA.
Number of subjects: 557
Study 39252591 — intervention group
Group type: EXPERIMENTAL
Intervention: CA strategies used in self-expandable TAVR devices (ACN2 and EP).
Number of subjects: 557
Study 39252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in poverty
Number of subjects: 5833
Study 39252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use
Number of subjects: 5833
Study 39252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy tobacco smoking
Number of subjects: 5833
Study 39252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a stable partner
Number of subjects: 5833